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ABSTRACT 
DNA mismatch repair (MMR) is a system that is highly conserved in both prokaryotes 
and eukaryotes. The heterodimer MutSα and a suite of associated proteins are essential 
in the recognition and repair of DNA afflicted with mispaired bases and short 
insertion/deletion loops, but is also implicated in funneling damaged cells towards 
apoptosis via a key conformational change that can be bound specifically by the small 
molecule reserpine. Molecular dynamics modeling and virtual screening were used to 
identify additional small molecule novel ligands with the predicted ability to selectively 
bind this “death” conformation of MutSα. These novel ligands were demonstrated to 
possess cytotoxicity similar to that of reserpine. As MMR deficiency has been 
demonstrated to confer a degree of resistance to some chemotherapeutic agents, 
exploiting this novel apoptotic pathway may prove to be a valid niche treatment in 
particular classes of cancers in which MMR proteins have been mutated. 
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Introduction and Literature Survey 
In both prokaryotes and eukaryotes, DNA replication is a tightly controlled and 
highly regulated process. This essential stage in the lifecycle of a cell is regulated by a 
suite of proteins that, collectively, unwind the DNA to be replicated, replicate the parent 
DNA, and terminate the replicative process once the daughter strands have been 
successfully polymerized (Frouin, Montecucco, Spadari, & Maga, 2003). Maintaining the 
integrity of the DNA molecule’s primary structure during replication is an essential 
process that is accomplished by a variety of biochemical pathways, such as the 
mismatch repair pathway.  
The DNA mismatch repair (MMR) system is responsible for the detection and 
resolution of two major forms of polymerase errors: partially extrahelical heterogenetic 
insertion/deletion loops (IDLs), and mismatched nucleotide bases (Jiricny, 2006). 
Deficiencies in MMR proteins most evidently present as increased microsatellite 
instability, a hypermutable phenotype that increases susceptibility to various forms of 
cancers, but particularly colorectal cancers (Boland and Goel, 2009). Additionally, 
deficient MMR systems may play a greater role in the decreased cytotoxicity of specific 
chemotherapeutic agents, such as the broad spectrum chemotherapeutic drug cisplatin, 
where deficiencies in the MMR pathways of cancer cells increased their resiliency to the 
drug 2-4 fold (Irving and Hall, 2001).  
The protein MutS (mutator S) and its eukaryotic homologs (mutator S homolog 
2, MSH3, and MSH6) are responsible for the initial recognition of DNA mismatches and 
the consequent formation of the primary protein/DNA heterodimer complex, which 
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then recruits other proteins and cofactors essential to the mismatch repair process 
(Jiricny, 2006). Specifically, MutS dimerizes to form a homodimer. In the event of 
irreconcilable DNA damage, these proteins (MutS and its eukaryotic homologs) possess 
additional regulatory functionality by promoting the activation of the caspase-mediated 
apoptotic pathway (Vasilyeva, 2009). Just how the prokaryotic MutS and the eukaryotic  
Table 1. A list of human MutS homologs, their component subunits, and their known funciton. 
Obtained from Jiricny (2006). 
Complex Components Function 
MutSα MSH2 + MSH6 Recognition of base-base 
mismatches and short IDLs 
MutSβ MSH2 + MSH3 Recognition of longer IDLs 
MutLα MLH1 + PMS2 Formation of ternary 
complex with DNA-bound 
MutSα 
MutLβ MLH1+ PMS1 Unknown 
 
MutSα/β heterodimeric complexes participate in the apoptotic caspase-signaling 
cascade remains subject to debate, with two competing hypothesis dominating 
academic contention. The “futile repair cycle” hypothesis posits an indirect role of MMR 
proteins in activating caspase-mediated apoptosis – instead of directly activating 
proteins within the caspase cascade, apoptosis is triggered as a result of DNA strand 
breakage formation following repeated “futile” repair attempts by the MMR system in 
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which mismatch damage persists. It is then through these standing strand breaks that 
the apoptotic pathway is initiated (Roos and Kaina, 2006). Conversely, the “direct 
signaling” hypothesis propounds a dual functionality for at least the MutSα complex in 
eukaryotes. According to this hypothesis, cell death is initiated by the MMR proteins 
themselves, particularly MutSα, through direct signaling that results in the activation of 
the caspase-mediated apoptotic-signaling cascade. (Roos and Kaina, 2006). This then 
suggests that there exist two distinct conformations for the MutSα heterodimer – a pro-
repair conformation in which DNA repair is promoted, and an alternative “death” 
conformation in which the protein abandons its repair function and instead promotes 
cell death via an apoptotic-signaling cascade (Salsbury, Clodfelter, Gentry, Hollis, and 
Scarpinato, 2006). Vasilyeva et al. (2009) suggested that both mechanisms could, and 
likely do, occur. It is further suggested that which conformation – and consequently, 
which functionality – MutSα assumes is dependent on the substrate located within the 
protein’s DNA binding groove; mismatched DNA promotes a “repair” conformation and 
response, and damaged DNA promotes a “death” conformation and response (Ling, 
2004; Salsbury et al., 2006). As each pathway acts independently of the other, and is 
ostensibly substrate dependent, it is possible to selectively activate the apoptotic 
pathway with novel ligands, which has been demonstrated with the drug reserpine, and 
its derivatives. 
 Reserpine is an FDA approved indole alkaloid drug isolated from the Indian 
snakeroot (Rauwolfia serpentine), and used historically as an antihypertensive in the 
regulation of blood pressure. Vasilyeva et al. (2009) identified reserpine as a possible 
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novel ligand capable of selectively binding the MutSα complex to a proposed “death 
conformation” via molecular dynamics simulation and virtual screening. The x-ray 
structure of the MutS complex from Escherichia coli complexed with DNA (of which the 
MutSα is a homolog) was used as a model for 3D virtual analysis of the active site in 
conjunction with novel ligands. The molecular dynamic simulation was used to estimate 
the inhibition constant Ki of novel ligands. Using this method, reserpine was identified as 
a potential novel ligand with a hypothetical twenty-fold affinity for the proposed 
apoptotic conformation of the MutSα heterodimeric complex over the repair 
conformation. Reserpine has been demonstrated to induce apoptosis via the 
MSH2/MSH6-mediated apoptotic pathway in vitro; however, the necessary 
concentrations needed for anti-tumour activity causes dangerous hypotension in vivo, 
and it is therefore not a viable chemotherapeutic agent in humans. Reserpine’s ability to 
effectively induce MMR-dependent apoptosis in cancer cells is, however, a proof-of-
concept that virtual analysis of molecular dynamics is an effective approach in 
identifying possible novel ligands to bind proteins to specific desired conformations 
(Vasilyeva et al., 2009). Thus, it should be possible to generate additional small-molecule 
novel ligands capable of binding the MSH2 subunit to its proposed “death” 
conformation. 
Protein/DNA Interaction 
 Just as prokaryotic DNA replication varies from its eukaryotic counterpart, so too 
does the MMR machinery vary in both models. In mammalian cells, different MMR 
machinery participates in the repair/abort pathways dependent on the type of DNA 
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damage encountered (Acharya, Wilson, Gradia, Kane, Guerrette, Marsischky, Kolodner, 
and Fishel, 1996). The heterodimeric MutSα initiates the repair of single-base 
mismatches and short insertion/deletion loops (IDLs) of one or two extrahelical  
nucleotides. Insertion/deletion loops that contain two or more extrahelical nucleotides 
are recognized by the related complex MutSβ, which is a heterodimer of MSH2 and 
MSH3 (Acharya et al., 1996; Palombo, Iaccarino, Nakajima, Ikejima, Shimada, and Jiricny, 
1996). In this way, the mammalian MMR system exhibits partial redundancy. The initial 
binding of the MutSα complex to heterogenetic duplex DNA is mediated by the two DNA 
binding domains (“clamp domains”) of the MutSα complex. Each subunit possesses a 
clamp domain, and it is only the clamp domain of the MSH6 subunit that actually 
contacts the nitrogenous bases of the DNA (and are thus the only part of the mechanism 
that is sequence-dependent) (Obmolova et al., 2000; Lamers et al., 2000).  
 
 Figure 1. A. Ribbon model of the MSH2/MSH6 heterodimer in complex with heterogenetic DNA 
(shown in black). B. View of the the complex's ATP binding domains, with ATP positioning 
included. Obtained from Hargreaves (2010).
 This anchoring is achieved by the 
(where ‘X’ is typically a negatively charged amino acid)
the MSH6 subunit of the 
from the minor groove at the nucleotide 
This protein/DNA interaction is ordinarily impossible due to electrostatic repulsion 
between the negatively charged side chains (the conserved glutamine and the variable 
amino acid ‘X’) and the negatively charg
a mispair event widens the minor groove of
these normally-repulsed side chains to occupy the groove with little difficulty, and 
results in a bending of the DNA by approxima
 
presence of a highly conserved Phe-X-
 present exclusively in domain I of 
MutSα complex, which approaches the daughter strand DNA 
base 3’ to the mispair (Lamers 
ed phosphate backbone of the duplex DNA, but 
 the heterogenetic duplex DNA, allowing 
tely 60° (Lamers et al., 2000
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Glu motif 
et al., 2000). 
; Jiricny, 2006). 
 This “kinked” DNA conformation, normally energetically unfavorable, is stabilized by its 
interaction with the rest of the domains of the 
hydrogen bonding and salt bridges
the major groove causes a transient puckering of the nucleotide sugars from the C2’
endoconformation that is typical of B type DNA to the more energetically favorable C3’
endoconformation that characterizes A 
surrounding the site of the base
However, these interactions occur only between the protein and the phosphate 
backbone – the binding and stabilizing of the DNA ar
independent (Lamers et al., 2000; 
Figure 2. Structural alteration between the C2' and C3' endoconformations of the deoxyribose sugar
ring. Also included is the syn
 
 
 
 
protein, which form a network 
. Additionally, the bending of the DNA 60
type DNA in the nucleotide bases immediately
-base mispair (Nag, 2007; Obmolova et al., 2000).
ound the mispair is sequence
Obmolova et al., 2000; Nag, 2007).  
/anti positioning of the attached guanine base. 
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An Overview of the Repair Pathway 
Once bound to the DNA at the site of the mispair, the MutSα complex undergoes 
a conformational change heralded by the exchange of the ADP molecule present in the 
MSH6 subunit for an ATP molecule. The new conformation causes the intercalated Phe-
X-Glu motif to release the DNA, allowing it to move along the DNA as a sliding clamp 
(Jiricny, 2006). This change in conformation from statically bound protein anchor to 
hydrolysis-independent sliding clamp is crucial for initiating the repair functionality of 
the pathway. Once this conformational transition has been completed, MutSα is free to 
slide along the DNA contour in either direction, although the direction in which it travels 
affects the downstream proteins that will be recruited and the subsequent directionality 
of strand degradation (Jiricny, 2006). The next step in the pathway involves the 
association of the MutSα complex with another MMR heterodimer, MutLα. This protein 
complex exists as a heterodimer of the MMR proteins MLH1 (MutL homolog-1) and 
PMS2 (post-meiotic segregation protein-1), and has been shown to complex with 
MutSα. The exact role of the resultant, likely transient ternary complex remains hitherto 
unclear (Plotz, Raedle, Brieger, Trojan, and Zeuzem, 2002; Plotz, Piiper, Wormek, 
Zeuzem, and Raedle, 2006; Jiricny, 2006). It is postulated that this interaction between 
heterodimers is necessary to mediate the ATP-dependent turnover of the MutSα 
complex, or/and alternatively mediate interactions between the functional MutSα 
subunits and associated MMR proteins at the strand excision site downstream of the 
mispair (Plotz et al., 2002). Regardless, MutLα has been experimentally shown to be an 
integral component of the MMR repair pathway, as mice with the component 
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monomers knocked out (PMS2
-/-
 and MLH1
-/-
) phenotypically express significantly 
increased microsatellite instability and tumorigenesis (Marra and Jiricny, 2003). The next 
step of the pathway is dependent on both the direction in which the sliding clamp 
travels along the DNA after it has been complexed with MutLα, and the presence of 
previously-formed strand breaks within the nascent daughter strand. As MMR 
functionality requires preexisting strand breaks in vitro, it is hypothesized that Okazaki 
fragment termini serve as these strand discontinuities in vivo (Ghodgaonkar, Lazzaro, 
Olivera-Pimentel, Artola-Borán, Cejka, Reijns, Jackson, Plevani, Muiz-Falconi, Jiricny, 
2013). MutSα/ MutLα clamps that move upstream along the DNA contour encounter 
the clamp-loading protein replication factor C (RFC) attached to the 5’ terminus of the 
single-strand break. The sliding clamp then promotes the displacement of RFC from the 
DNA, and recruits the exonuclease EXO1 (exonuclease-1). EXO1 initiates the subsequent 
degradation of the daughter strand in the 5’3’ direction, with the resultant single-
stranded DNA stabilized by replication protein A (RPA) (Jiricny, 2006). Once the 
mismatch has been successfully excised by EXO1, EXO1’s exonuclease activity is 
simultaneously no longer promoted by MutSα and actively inhibited by MutLα. 
Concurrently, DNA polymerase δ is promoted to load at the 3’ terminus of the original 
strand break by its processivity factor proliferating cell nuclear antigen (PCNA). The 
newly-excised strand allows DNA polymerase δ to reattempt fidelitous DNA replication 
across the site of the previous mispair, and the remaining nick is ligated by DNA ligase I 
(Yang, 2000; Jiricny, 2006). This process is largely the same for MutSα/ MutLα clamps 
that move downstream from the initial mispair, with reversed polarity. Upon diffusing 
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downstream, the MutSα/ MutLα clamp first encounters a PCNA molecule bound to the 
3’ terminus of the Okazaki fragment, with an RFC molecule bound nearby. Upon contact 
with PCNA, the MutSα/ MutLα clamp complex recruits EXO1 to excise nucleotides in a 
3’5’ orientation – 5’3’ exonuclease activity is prevented by the downstream RFC 
molecule. Exonuclease activity continues upstream until the mispaired base has been 
removed, at which point EXO1 exonuclease activity is inhibited. RPA molecules stabilize 
the exposed single-strand while DNA polymerase δ loads at the site at which EXO1 
exonuclease activity ceased (DNA polymerase δ possesses only 5’3’ replication 
activity). Finally, DNA ligase I seals the remaining nick (Yang, 2000; Jiricny, 2006).  
MMR Role in Apoptosis Activation is Significant but Poorly Understood 
 Mismatch repair proteins have been repeatedly implicated in the activation of 
cell death (Lin, 2004; Jiricny, 2006; Vasilyeva et al., 2009), but how they interact with the 
apoptotic machinery of the cell remains poorly understood (Lin, 2004; Vasilyeva et al., 
2009). Currently, two hypotheses are considered most likely: the futile repair cycle 
model and the direct signalling model, with evidence suggesting that both pathways 
may be used situationally by the cell (Salsbury et al., 2006). The futile repair cycle 
hypothesis suggests that repeated unsuccessful repair attempts lead to standing strand 
degradation, which initiates apoptotic pathways and funnels the cell towards death 
(Mello, Acharya, Fishel, and Essigmann, 1996). Conversely, the direct signalling 
hypothesis proposes a more involved role by the MMR system in initiating eukaryotic 
cell death in which a conformational change in the mismatch recognition complex 
MutSα results in the protein actively recruiting factors that funnel the cell towards 
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apoptosis (Salsbury et al., 2006). Importantly, Vasilyeva et al. (2009) established that 
this “death” conformation could be selectively activated by small-molecule ligands, and 
that resultant cell death does proceed through the caspase-mediated apoptotic 
pathway. Additionally, it has been shown that cells with repair-deficient MMR proteins 
are still susceptible to cisplatin-induced cytotoxicity, which further lends credence to 
two discrete functions of the MutSα complex (Lin et al., 2004; Salsbury et al., 2006). 
 Materials and Methods 
 Virtual screening and molecular dynamic simulations were performed in 
collaboration with Wake Forest University. AutoDock 3.0 was used to screen prospective 
compounds identified by molecular dynamics simulation analysis, and a list of potential 
molecules calculated to hypothetically bind the MutSα “death” conformation with a 
high degree of fidelity (according to the inhibition constant, Ki) was generated. Protocol 
for the dynamics simulation and virtual screening was as described elsewhere (Morris, 
Goodsell, Halliday, Huey, Hart, Belew, and Olson, 1998; Salsbury et al., 2006). 
Prospective compounds were then subjected to the colorimetric CellTiter 96
®
 AQueous 
One Solution Cell Proliferation Assay
®
 (MTS assay) to determine cell viability. PC3 
prostate cancer cells were cultured in standard growth media and transferred to 96-well 
plates. CellTiter 96
®
 AQueous One Solution Reagent (containing a tetrazolium compound 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine ethosulfate; 
PES)) were added to the cells and incubated for 24 hours. The drugs to be tested in 
addition to a reserpine control were dissolved in an appropriate solvent (typically DMSO 
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and acetic acid), and a stock solution of drug with sufficient volume for the amount of 
plated cells for any given assay was prepared. Solvents used were tested for 
cytotoxicity. A serial dilution was then performed to generate 1/64, 1/32, 1/16, 1/8, and 
1/4 dilutions from the stock, and the last aliquot left as a control, receiving only the 
DMSO/acetic acid solvent. The drug dilutions were then added to the plate in triplicates, 
incubated for 1-1.5 hours, and the absorbance read at 490nm by a 96-well plate reader. 
The amount of formazan product formed as the MTS is metabolized correlates 
proportionally to the amount of viable cells left in culture. This data was then used to 
generate a “kill curve,” or a curve illustrating the rate of cancer cell death for each 
concentration of tested drug, and compared to the reserpine control curve to determine 
comparative efficacy.  
Results 
Molecular Analysis Identified Reserpine-like Compounds 
 Following molecular analysis via virtual screening and molecular dynamics 
simulation, two commercially available drugs were identified as being hypothetically 
able to bind the MutSα “death” conformation in the same way as reserpine. These two 
drugs – C19H15N503S and P701100, shortened to “C19” and “P7” respectively – were 
used to perform a cell viability assay, where their induced cytotoxicity was compared to 
the reserpine control. 
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Small Molecule Novel Ligands Express Reserpine-like Cytotoxicity in vitro 
 Molecular modeling suggested that P7 and C19 would selectively bind the 
“death” conformation of the MutSα heterodimer much in the same way that reserpine 
does, and trigger cell death in a similar manner. Thus, we expected the cytotoxicity of 
these compounds to be at least as effective as reserpine. Indeed, experimental 
cytotoxicity of P7 and C19 proved to be just as effective as that of reserpine, with P7 
performing slightly better at the highest concentration of drug (Figures 3, 4).  
 
Figure 3. An MTS cell viability assay illustrates the cytotoxicity shared by the reserpine control 
and its behavioural analogs, P7 and C19, at increasing levels of drug concentration. 
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Figure 4. Log transformed version of Figure 3. Note: we observed small concentrations of drugs 
stimulating cell survival, resulting in a % cell viability greater than 100, which cannot be plotted. 
Discussion 
 In this experiment, we confirmed molecular modeling and 3D virtual screening of 
proteins and known, indexed compounds to be an effective method in identifying novel 
ligands capable of selectively binding proteins to desired conformations. Indeed, we 
were able to identify a novel ligand (P7) that may prove to induce MutSα-mediated 
apoptosis more effectively than reserpine, and yet other compounds yet to have their 3-
dimensional structure elucidated and indexed may prove to be more effective still. This 
would mean that a greater amount of cells could be killed with lower concentrations of 
drugs, which reduce the risk of serious side effects in vivo – the major limiting factor of 
reserpine and its derivatives as anything more than a niche chemotherapeutic.  
 More broadly, demonstrating the efficacy of a chemotherapeutic agent in vitro is 
the necessary precursor to identifying an agent that is viable in vitro; thus, by successful 
identification of novel and effective cytotoxic agents in vitro, we open the door to future 
in vivo testing of agents that may exploit a novel pathway not currently used clinically, 
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such as the MutSα-mediated apoptotic pathway. Indeed, since deficient MMR proteins 
have been implicated in conferring some degree of cytotoxic resistance to the cancer 
cells in which they are mutated by not triggering the apoptotic pathway via their 
naturally damaged DNA substrate (Irving and Hall, 2001), being able to bypass the DNA 
trigger with a novel ligand may be an effective niche treatment in some cancers. Of 
particular interest in that regard are colorectal cancers, in which MMR systems are 
commonly deficient (Boland and Goel, 2010). Exploiting the apoptotic functionality of 
MMR proteins may prove to be an effective niche treatment of this class of cancers. 
 Additionally, our results support the existence of the direct-signaling hypothesis. 
By identifying novel ligands that were predicted to fit a proposed pro-apoptotic 
conformation and subsequently observing cytotoxicity upon the treatment of cells with 
those ligands, we support the direct involvement of MMR proteins in funneling a cell 
with irreparable DNA damage towards apoptosis. However, additional caspase analysis 
needs to be performed to further substantiate MMR proteins initiating apoptosis. 
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